Ratings for NeoGenomics (NASDAQ:NEO) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $21.25, along with a high estimate of $24.00 and a low estimate of $19.00. A decline of 6.26% from the prior average price target is evident in the current average.

Analyzing Analyst Ratings: A Detailed Breakdown

A comprehensive examination of how financial experts perceive NeoGenomics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NeoGenomics's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on NeoGenomics analyst ratings.

Get to Know NeoGenomics Better

Understanding the Numbers: NeoGenomics's Finances

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: NeoGenomics displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 17.99%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: NeoGenomics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -12.19%, the company may face hurdles in effective cost management.

Return on Equity (ROE): NeoGenomics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.95%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): NeoGenomics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.1%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: NeoGenomics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.64.

Analyst Ratings: Simplified

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.